NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

遺傳性檢驗市場調查報告:各疾病類型-至2025年的預測-COVID-19累積的影響

Hereditary Testing Market Research Report by Disease Type, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 996084
出版日期 內容資訊 英文 190 Pages
商品交期: 最快1-2個工作天內
價格
遺傳性檢驗市場調查報告:各疾病類型-至2025年的預測-COVID-19累積的影響 Hereditary Testing Market Research Report by Disease Type, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 190 Pages
簡介

全球遺傳性檢驗的市場規模,2020年成為41億4,768萬美元/36億3,676萬歐元。該市場,預計至2025年末為59億8,293萬美元/52億4,594萬歐元。

COVID-19是影響幾乎全部產業的無與倫比的世界公共衛生緊急事件,在預測期間內預計帶給產業的成長長期性的影響。目前進行的調查擴大了框架,以確保包括潛在的COVID-19問題和發展途徑。 本報告提供有關COVID-19的見解,其中考慮了消費者行為和需求的變化,購買方式,供應鏈的新路由,當前市場力量的動態以及政府的重要介入等COVID-19對市場的影響相關洞察。

本報告提供遺傳性檢驗市場相關調查,市場概要,以及各疾病類型,各地區的趨勢,COVID-19累積的影響,及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

  • 調查的目的
  • 市場區隔和範圍
  • 調查對象年
  • 貨幣和價格
  • 語言
  • 限制事項
  • 利害關係者

第2章 調查手法

  • 調查流程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:調查設備
    • 收集:資料來源
    • 分析:資料的解釋
    • 制定:資料檢驗
    • 公開:調查報告
    • 重複:報告的更新
  • 調查的實行
    • 開始:調查流程
    • 計劃:調查計劃作成
    • 實行:調查實施
    • 檢驗:發現與分析
    • 出版物:調查報告
  • 調查成果

第3章 摘要整理

  • 簡介
  • 市場預測
  • 各疾病類型預測
  • 各地區預測
  • 其他各競爭公司預測

第4章 市場概要

  • 簡介
  • COVID-19累積的影響

第5章 市場洞察

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • 波特五力分析
    • 新加入業者的威脅
    • 替代品的威脅
    • 客戶談判力
    • 供給企業談判力
    • 產業的競爭

第6章 全球遺傳性檢驗市場,各疾病類型

  • 遺傳性癌症檢驗
    • 乳癌
    • 子宮頸癌
    • 大腸癌
    • 肺癌
    • 黑色素瘤
    • 卵巢癌
    • 胰臟癌
    • 前列腺癌
    • 肉瘤
    • 胃/胃癌
    • 子宮癌
  • 遺傳性非癌症檢驗
    • 遺傳基因檢驗
  • 新生兒的遺傳基因篩檢
  • 非侵入性產前檢查(NIPT)及攜帶者篩檢檢驗
  • 胚胎著床前遺傳基因診斷和篩檢

第7章 南北美洲的遺傳性檢驗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第8章 亞太地區的遺傳性檢驗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第9章 歐洲,中東、非洲的遺傳性檢驗市場

  • 法國
  • 德國
  • 義大利
  • 荷蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合大公國
  • 英國

第10章 競爭情形

  • FPNV定位矩陣
    • 象限
    • 事業策略
    • 產品的滿意度
  • 市場排行榜分析
  • 市場佔有率分析
  • 其他競爭公司的SWOT分析
  • 競爭模式
    • 合併和收購
    • 協定,合作,及夥伴關係
    • 新產品的銷售與強化
    • 投資與資金籌措
    • 獎,獎勵,擴大

第11章 企業的實用性簡介

  • 23andMe, Inc.
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Beijing Genomics Institute
  • Bio-Helix Co. Ltd
  • Bio-Rad Laboratories, Inc.
  • Biocartis Group NV
  • CENTOGENE N.V.
  • CooperSurgical, Inc.
  • CSL Ltd.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Fulgent Genetics, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Konica Minolta, Inc.
  • Laboratory Corporation of America Holdings
  • Medgenome
  • Myriad Genetics, Inc
  • Natera Inc
  • Pacific Biosciences of California, Inc.
  • Pathway Genomics Corporation
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sophia Genetics
  • Thermo Fisher Scientific, Inc.
  • Twist Bioscience

第12章 附錄

  • 討論指南
  • 許可證和價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-A339DAEFA86E

The Global Hereditary Testing Market size was estimated at USD 4,109.41 Million in 2020 and expected to reach USD 4,423.45 Million in 2021, at a Compound Annual Growth Rate (CAGR) 7.98% to reach USD 6,514.03 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Hereditary Testing to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Disease Type, the Hereditary Testing Market was studied across Hereditary Cancer Testing, Hereditary Non-cancer Testing, Newborn Genetic Screening, Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests, and Preimplantation Genetic Diagnosis & Screening. The Hereditary Cancer Testing is further studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma, Stomach/Gastric Cancer, and Uterine Cancer. The Hereditary Non-cancer Testing is further studied across Genetic Tests.

Based on Geography, the Hereditary Testing Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Hereditary Testing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Hereditary Testing Market, including 23andMe, Inc., Abbott Laboratories, Agilent Technologies, Inc., Beijing Genomics Institute, Bio-Helix Co. Ltd, Bio-Rad Laboratories, Inc., Biocartis Group NV, CENTOGENE N.V., CooperSurgical, Inc., CSL Ltd., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Fulgent Genetics, Inc., Igenomix, Illumina, Inc., Invitae Corporation, Konica Minolta, Inc., Laboratory Corporation of America Holdings, Medgenome, Myriad Genetics, Inc, Natera Inc, Pacific Biosciences of California, Inc., Pathway Genomics Corporation, PerkinElmer, Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, Sophia Genetics, Thermo Fisher Scientific, Inc., and Twist Bioscience.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Hereditary Testing Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Hereditary Testing Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hereditary Testing Market?
  • 4. What is the competitive strategic window for opportunities in the Global Hereditary Testing Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Hereditary Testing Market?
  • 6. What is the market share of the leading vendors in the Global Hereditary Testing Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Hereditary Testing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Disease Type Outlook
  • 3.4. Geography Outlook
  • 3.5. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Exploration for changes or variants, in DNA to find root cause of potential disease
      • 5.1.1.2. Increased screening by pregnant women
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursement policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborative product development
      • 5.1.3.2. R&D on advance Genome sequencing
      • 5.1.3.3. Attractive investment and amalgamation activity within value chain
    • 5.1.4. Challenges
      • 5.1.4.1. Uncertain outcomes
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Hereditary Testing Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Hereditary Cancer Testing
    • 6.2.1. Breast Cancer
    • 6.2.2. Cervical Cancer
    • 6.2.3. Colorectal Cancer
    • 6.2.4. Lung Cancer
    • 6.2.5. Melanoma
    • 6.2.6. Ovarian Cancer
    • 6.2.7. Pancreatic Cancer
    • 6.2.8. Prostate Cancer
    • 6.2.9. Sarcoma
    • 6.2.10. Stomach/Gastric Cancer
    • 6.2.11. Uterine Cancer
  • 6.3. Hereditary Non-cancer Testing
    • 6.3.1. Genetic Tests
      • 6.3.1.1. Cardiac Diseases
      • 6.3.1.2. Other Diseases
      • 6.3.1.3. Rare Diseases
  • 6.4. Newborn Genetic Screening
  • 6.5. Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests
  • 6.6. Preimplantation Genetic Diagnosis & Screening

7. Americas Hereditary Testing Market

  • 7.1. Introduction
  • 7.2. Argentina
  • 7.3. Brazil
  • 7.4. Canada
  • 7.5. Mexico
  • 7.6. United States
    • 7.6.1. California
    • 7.6.2. Florida
    • 7.6.3. Illinois
    • 7.6.4. New York
    • 7.6.5. Ohio
    • 7.6.6. Pennsylvania
    • 7.6.7. Texas

8. Asia-Pacific Hereditary Testing Market

  • 8.1. Introduction
  • 8.2. China
  • 8.3. India
  • 8.4. Indonesia
  • 8.5. Japan
  • 8.6. Malaysia
  • 8.7. Philippines
  • 8.8. South Korea
  • 8.9. Thailand

9. Europe, Middle East & Africa Hereditary Testing Market

  • 9.1. Introduction
  • 9.2. France
  • 9.3. Germany
  • 9.4. Italy
  • 9.5. Netherlands
  • 9.6. Qatar
  • 9.7. Russia
  • 9.8. Saudi Arabia
  • 9.9. South Africa
  • 9.10. Spain
  • 9.11. United Arab Emirates
  • 9.12. United Kingdom

10. Competitive Landscape

  • 10.1. FPNV Positioning Matrix
    • 10.1.1. Quadrants
    • 10.1.2. Business Strategy
    • 10.1.3. Product Satisfaction
  • 10.2. Market Ranking Analysis
  • 10.3. Market Share Analysis, By Quadrant
  • 10.4. Market Share Analysis, By Company
  • 10.5. Competitive Scenario
    • 10.5.1. Merger & Acquisition
    • 10.5.2. Agreement, Collaboration, & Partnership
    • 10.5.3. New Product Launch & Enhancement
    • 10.5.4. Investment & Funding
    • 10.5.5. Award, Recognition, & Expansion

11. Company Usability Profiles

  • 11.1. 23andMe, Inc.
  • 11.2. Abbott Laboratories
  • 11.3. Agilent Technologies, Inc.
  • 11.4. Beijing Genomics Institute
  • 11.5. Bio-Helix Co. Ltd
  • 11.6. Bio-Rad Laboratories, Inc.
  • 11.7. Biocartis Group NV
  • 11.8. CENTOGENE N.V.
  • 11.9. CooperSurgical, Inc.
  • 11.10. CSL Ltd.
  • 11.11. Eurofins Scientific SE
  • 11.12. F. Hoffmann-La Roche Ltd
  • 11.13. Fulgent Genetics, Inc.
  • 11.14. Igenomix
  • 11.15. Illumina, Inc.
  • 11.16. Invitae Corporation
  • 11.17. Konica Minolta, Inc.
  • 11.18. Laboratory Corporation of America Holdings
  • 11.19. Medgenome
  • 11.20. Myriad Genetics, Inc
  • 11.21. Natera Inc
  • 11.22. Pacific Biosciences of California, Inc.
  • 11.23. Pathway Genomics Corporation
  • 11.24. PerkinElmer, Inc.
  • 11.25. Quest Diagnostics Incorporated
  • 11.26. Siemens Healthineers AG
  • 11.27. Sophia Genetics
  • 11.28. Thermo Fisher Scientific, Inc.
  • 11.29. Twist Bioscience

12. Appendix

  • 12.1. Discussion Guide
  • 12.2. License & Pricing
  • 12.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEREDITARY TESTING MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL HEREDITARY TESTING MARKET: MARKET DYNAMICS
  • FIGURE 5. GLOBAL HEREDITARY TESTING MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 6. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2020 VS 2026 (%)
  • FIGURE 7. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 8. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2026
  • FIGURE 9. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2026 (USD MILLION)
  • FIGURE 10. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 11. GLOBAL HEREDITARY TESTING MARKET SIZE, BY BREAST CANCER, 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL HEREDITARY TESTING MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CERVICAL CANCER, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CERVICAL CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COLORECTAL CANCER, 2018-2026 (USD MILLION)
  • FIGURE 16. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. GLOBAL HEREDITARY TESTING MARKET SIZE, BY LUNG CANCER, 2018-2026 (USD MILLION)
  • FIGURE 18. GLOBAL HEREDITARY TESTING MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 19. GLOBAL HEREDITARY TESTING MARKET SIZE, BY MELANOMA, 2018-2026 (USD MILLION)
  • FIGURE 20. GLOBAL HEREDITARY TESTING MARKET SIZE, BY MELANOMA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 21. GLOBAL HEREDITARY TESTING MARKET SIZE, BY OVARIAN CANCER, 2018-2026 (USD MILLION)
  • FIGURE 22. GLOBAL HEREDITARY TESTING MARKET SIZE, BY OVARIAN CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 23. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PANCREATIC CANCER, 2018-2026 (USD MILLION)
  • FIGURE 24. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PANCREATIC CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 25. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PROSTATE CANCER, 2018-2026 (USD MILLION)
  • FIGURE 26. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PROSTATE CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 27. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SARCOMA, 2018-2026 (USD MILLION)
  • FIGURE 28. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SARCOMA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 29. GLOBAL HEREDITARY TESTING MARKET SIZE, BY STOMACH/GASTRIC CANCER, 2018-2026 (USD MILLION)
  • FIGURE 30. GLOBAL HEREDITARY TESTING MARKET SIZE, BY STOMACH/GASTRIC CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 31. GLOBAL HEREDITARY TESTING MARKET SIZE, BY UTERINE CANCER, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL HEREDITARY TESTING MARKET SIZE, BY UTERINE CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2026 (USD MILLION)
  • FIGURE 34. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2026 (USD MILLION)
  • FIGURE 36. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 37. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARDIAC DISEASES, 2018-2026 (USD MILLION)
  • FIGURE 38. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARDIAC DISEASES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 39. GLOBAL HEREDITARY TESTING MARKET SIZE, BY OTHER DISEASES, 2018-2026 (USD MILLION)
  • FIGURE 40. GLOBAL HEREDITARY TESTING MARKET SIZE, BY OTHER DISEASES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 41. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RARE DISEASES, 2018-2026 (USD MILLION)
  • FIGURE 42. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RARE DISEASES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 43. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NEWBORN GENETIC SCREENING, 2018-2026 (USD MILLION)
  • FIGURE 44. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NEWBORN GENETIC SCREENING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 45. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING (NIPT) & CARRIER SCREENING TESTS, 2018-2026 (USD MILLION)
  • FIGURE 46. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING (NIPT) & CARRIER SCREENING TESTS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 47. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS & SCREENING, 2018-2026 (USD MILLION)
  • FIGURE 48. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS & SCREENING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 49. AMERICAS HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 50. AMERICAS HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 51. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 52. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 53. BRAZIL HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 54. CANADA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 55. MEXICO HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 56. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 57. CALIFORNIA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 58. FLORIDA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 59. ILLINOIS HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 60. NEW YORK HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 61. OHIO HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 62. PENNSYLVANIA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. TEXAS HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 64. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 65. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 66. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 67. CHINA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 68. INDIA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. INDONESIA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 70. JAPAN HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 71. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 72. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 74. THAILAND HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 75. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 76. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 77. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 78. FRANCE HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 79. GERMANY HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 80. ITALY HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 81. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 82. QATAR HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 83. RUSSIA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 84. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 85. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 86. SPAIN HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 87. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 88. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 89. GLOBAL HEREDITARY TESTING MARKET: FPNV POSITIONING MATRIX
  • FIGURE 90. GLOBAL HEREDITARY TESTING MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 91. GLOBAL HEREDITARY TESTING MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 92. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL HEREDITARY TESTING MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL HEREDITARY TESTING MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL HEREDITARY TESTING MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CERVICAL CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL HEREDITARY TESTING MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL HEREDITARY TESTING MARKET SIZE, BY MELANOMA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL HEREDITARY TESTING MARKET SIZE, BY OVARIAN CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PANCREATIC CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PROSTATE CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SARCOMA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL HEREDITARY TESTING MARKET SIZE, BY STOMACH/GASTRIC CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL HEREDITARY TESTING MARKET SIZE, BY UTERINE CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARDIAC DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. GLOBAL HEREDITARY TESTING MARKET SIZE, BY OTHER DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RARE DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NEWBORN GENETIC SCREENING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING (NIPT) & CARRIER SCREENING TESTS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS & SCREENING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. AMERICAS HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. AMERICAS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. BRAZIL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. CANADA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. MEXICO HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. CALIFORNIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. FLORIDA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. ILLINOIS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. NEW YORK HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. OHIO HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. PENNSYLVANIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. TEXAS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. CHINA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. INDIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. INDONESIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. JAPAN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. THAILAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. FRANCE HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. GERMANY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. ITALY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. QATAR HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. RUSSIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. SPAIN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. GLOBAL HEREDITARY TESTING MARKET: SCORES
  • TABLE 63. GLOBAL HEREDITARY TESTING MARKET: BUSINESS STRATEGY
  • TABLE 64. GLOBAL HEREDITARY TESTING MARKET: PRODUCT SATISFACTION
  • TABLE 65. GLOBAL HEREDITARY TESTING MARKET: RANKING
  • TABLE 66. GLOBAL HEREDITARY TESTING MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 67. GLOBAL HEREDITARY TESTING MARKET: SHARE, BY COMPANY, 2020
  • TABLE 68. GLOBAL HEREDITARY TESTING MARKET: MERGER & ACQUISITION
  • TABLE 69. GLOBAL HEREDITARY TESTING MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 70. GLOBAL HEREDITARY TESTING MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 71. GLOBAL HEREDITARY TESTING MARKET: INVESTMENT & FUNDING
  • TABLE 72. GLOBAL HEREDITARY TESTING MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 73. GLOBAL HEREDITARY TESTING MARKET: LICENSE & PRICING
  • TABLE 74. GLOBAL HEREDITARY TESTING MARKET: CONTACT DETAILS